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ABSTRACT
Purpose: The feasibility, in terms of safety and
potential efficacy, of a new drug combination
for binocular use as a noninvasive
pharmacological solution for treating
presbyopia was examined.
Methods: Fourteen emmetropic presbyopic
subjects (28 eyes) were given one drop of the
preparation under study in each eye. For each
patient, the uncorrected distance visual acuity,
uncorrected near visual acuity, near and far
refraction, best corrected visual acuity, best
corrected far-near visual acuity, photopic and
scotopic pupil size, Schirmer’s test, endothelial
cell count, intraocular pressure, keratometry,
pachymetry, and anterior chamber depth were
all performed or assessed prior to the
administration of the eye drops and then 0.5,
1, 2, 3, 4, and 5 h, 1 week, and 1 month
post-administration prospectively in each eye
and binocularly.
Results: The results showed that near
uncorrected visual acuity improved by about
2–3 lines from baseline in each eye and
binocularly. There was no degradation in
uncorrected far vision in each eye and
binocularly in any patient. Refractive
measurements performed in this study showed
there was a maximum myopic shift of just 0.5 D
that progressively reduced and disappeared at
4 h.
Conclusion: The new topical drug treatment
analyzed herein significantly improved near
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vision without affecting far vision. This
binocular pharmacologic treatment of
presbyopia has the potential to ameliorate the
reading vision of presbyopes and possesses the
advantages of a nonmonovision therapy. A
randomized, controlled, double-masked
clinical trial with a twice-a-day treatment
schedule is ongoing at our institution.
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INTRODUCTION
Presbyopia, which is due to progressive
age-related accommodative loss, begins to
affect near visual tasks at around 40 years of
age, and is associated with substantial negative
effects on vision-targeted health-related quality
of life [1]. In 2015, more than 2.5 billion people
around the world were aged 40 years or older;
given that the global population is growing and
ageing, presbyopia will affect even more people
in the future [2]. However, the pathophysiology
of presbyopia is poorly understood, so the
correction of presbyopia and the restoration of
accommodation are among the most important
targets of ophthalmology research. Although
surgical compensation for presbyopia has
improved over the past decade, it is still
limited, so there has recently been increasing
interest in nonsurgical treatments [3]. Topical
treatment of presbyopia is an attractive
approach which, if available and effective,
would be the treatment of choice for many
patients. The few potential topical treatments
for presbyopia that are currently being studied
claim to work on different aspects of the
accommodative process, but each of these
approaches presents some disadvantages [4–7].
The topical treatment presented herein
contains a parasympathetic, a NSAID, two
alpha-agonist agents, and an
anticholinesterase agent, is administered
bilaterally, and promises to ameliorate the
symptoms of presbyopia through
pharmacological stimulation of iris and ciliary
muscle, thus minimizing the drawbacks
associated with a purely parasympathetic
action [8]. Here, we report the initial outcomes
obtained in a pilot investigation with the new
drug combination for binocular use in
presbyopic patients.
METHODS
This pilot study was begun after approval was
obtained from the ethics committee of
Fundacio´n Oftalmolo´gica Vejarano in
Popaya´n, Colombia. Each participant provided
written informed consent, and the study
followed the tenets of the Declaration of
Helsinki. The pharmacological stimulation
protocol was developed and submitted for
patent in 10 countries by Dr. Vejarano, who
had been using his own product and achieving
satisfactory results with it for five and a half
years previously (since July 2010) [9]. The study
group comprised 14 presbyopic subjects (28
eyes): 9 natural emmetropes and 5
stable emmetropes post LASIK surgery, with an
average age of 48.21 years (range 41–55 years).
Participants were randomly selected volunteers.
Presbyopia was considered to be present if the
patient needed to use a spectacle lens C ?1.00 D
to read a print size of Jaeger 0.8. Each subject
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was given only one drop of the ophthalmic
formulation containing pilocarpine 0.247%,
phenylephrine 0.78%, polyethyleneglycol
0.09%, nepafenac 0.023%, pheniramine
0.034%, and naphazoline 0.003% in each eye.
All of the drugs administered in this study are
approved by the US Food and Drug
Administration and have been used for years
as safe and effective agents for treating ocular
pathologies. Various ophthalmologic
measurements were taken prior to the
administration of the eye drops and then 0.5,
1, 2, 3, 4, and 5 h, 1 week, and 1 month post
administration in each eye and binocularly. The
measurements, which were performed by the
same independent examiner in the same room
with the same instruments, included
uncorrected distance (UDVA) and near
(UNVA) visual acuity, far and near refraction,
best spectacle-corrected distance (CDVA) and
near (CNVA) visual acuity, near visual acuity
with best far spectacle correction (CFNVA),
photopic and scotopic pupil size, Schirmer’s
test, endothelial cell count, intraocular
pressure, keratometry, pachymetry, and
anterior chamber depth. Distance visual acuity
was measured using the standard Snellen
projector chart at 4 m. Near visual acuity was
assessed at 40 cm using a hand-held Rosenbaum
chart with Jaeger notation, always employing
the same luminosity of 160 cd/m2. Pupil
diameter was measured using an AL-Scan
optical biometer (Nidek Co., Ltd., Japan), a
Pentacam (Oculus Optikgera¨te GmbH,
Germany), and an auto ref/keratometer (Nidek
Co., Ltd.). ECC was measured using a CellCheck
clinical specular microscope (Konan Medical
Inc., Japan). Intraocular pressure was measured
with a Goldmann AT-900 applanation
tonometer (Haag-Streit AG, Switzerland) and a
Pascal dynamic contour tonometer (Ziemer
Ophthalmic Systems AG, Switzerland).
Keratometry was performed using the auto ref/
keratometer (Nidek Co.). Pachymetry and
anterior chamber depth were measured with
the Pentacam (Oculus Optikgera¨te GmbH). The
inclusion criteria applied admitted patients who
were aged between 40 and 65 years, emmetropic
(cycloplegic spherical equivalent, ±1.00 D;
astigmatism, B0.50 D), had a binocular UDVA
of at least 20/25, and had no additional ocular
or systemic pathology. None of the patients
included in the study had received any chronic
mydriatic or miotic therapy previously. During
the study, the subjects were closely monitored
and regularly asked to report the grade of
satisfaction and any adverse effects; although
this pilot study was designed to assess the
feasibility of applying a single drop to each
eye, the topical formulation is intended to for
twice-daily use: once in the morning and once
in the afternoon before performing near visual
tasks. Due to the characteristics of the data, a
Friedman test was run to determine if there
were any significant changes in the values of the
monitored variables during the study period
(from 30 min to 1 month after administration)
in the analyzed eyes. Pairwise comparisons were
performed with a Bonferroni correction for
multiple comparisons (SPSS, 2015) to compare
the post-instillation data with baseline.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients before they were included in the study.
RESULTS
Table 1 summarizes the data for some variables
of particular interest. Figures 1, 2, 3, and 4
Ophthalmol Ther (2016) 5:63–73 65
present the time trends for the variables, which
show significant changes from 30 min to
1 month after administration. Pairwise
comparisons (Bonferroni corrected) were
performed between the post- and
pre-administration values of each variable,
and significant differences are marked by
asterisks (*) in the figures. Statistically
significant changes in photopic pupil
diameter (v2(8) = 68.581, p\0.001), scotopic
pupil diameter (v2(8) = 30.856, p\0.001),
intraocular pressure (v2(8) = 52.507,
p\0.001), CFNVA (v2(8) = 22.467, p\0.004),
binocular CFNVA (v2(8) = 61.685, p\0.001),
UDVA (v2(8) = 20.358, p\0.009), UNVA
(v2(8) = 95.324, p\0.001), binocular UNVA
(v2(8) = 101.205, p\0.001), binocular UDVA
(v2(8) = 37.989, p\0.001), spherical
equivalent (v2(8) = 118.524, p\0.001), and
best near addition (v2(8) = 25.213, p\0.001)
were observed. However, clinically relevant
improvements over time were only observed
in binocular UNVA (Fig. 2c), with an
improvement of C3 lines noted at 5 h in 6
patients (42.9% of the total); UNVA (Fig. 3b),
with an improvement of C3 lines seen at 5 h
in 7 patients (50.0% of the total); and
spherical equivalent (Fig. 4b), with an
improvement obtained at 3 h (0.32 ± 0.55
versus 0.03 ± 0.54). Notably, binocular
(Fig. 2a) and monocular (Fig. 3a) UDVA did
not show clinically relevant changes. Pupil
diameter was significantly increased under
photopic conditions until the first hour had
elapsed after adminstration, and was
significantly decreased under scotopic
conditions between 4 and 5 h after
instillation of the topical treatment. Patient
satisfaction was probed by asking them if they
were still enjoying the improved near vision
that they had after the eye drops were applied,
and whether they would like to continue
using the eye drops in order to maintain this
enhanced near vision. All patients answered
affirmatively to the question. No adverse
effects were reported.
Table 1 Mean initial value (M), standard deviation in that value (SD), and range of initial values for each variable that
showed a signiﬁcant change in value after the instillation of eye drops into the 28 studied eyes
Parameter M – SD (range)
Near visual acuity with best far spectacle correction (Jaeger) 4.81 ± 2.75 (10 to 1)
Best near addition (D) 1.85 ± 0.55 (1 to 2.75)
Binocular near visual acuity with best far spectacle correction (Jaeger) 3.27 ± 2.03 (8 to 1)
Binocular far uncorrected visual acuity (logMAR) 0.01 ± 0.04 (0.1 to 0)
Binocular near uncorrected visual acuity (Jaeger) 3.63 ± 2.59 (8 to 1)
Defocus equivalent (D) 0.72 ± 0.50 (0.25 to 2.75)
Far uncorrected visual acuity (logMAR) 0.08 ± 0.09 (0.3 to 0)
Intraocular pressure (mmHg) 14 ± 2 (10 to 17)
Near uncorrected visual acuity (Jaeger) 5.06 ± 3.47 (13 to 1)
Photopic pupil diameter (mm) 2.99 ± 0.59 (2.04 to 4.19)
Scotopic pupil diameter (mm) 4.73 ± 0.45 (4.1 to 5.7)
Spherical equivalent (D) 0.32 ± 0.55 (-1.0 to 1.0)
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Fig. 1 Trends in best near addition (a), monocular (b), and binocular (c) near visual acuity with best far spectacle
correction over time from 30 min to 1 month after instillation of the eye drops into the 28 studied eyes. Asterisks indicate
values that are signiﬁcantly different from the baseline. Best near addition and monocular near visual acuity with best far
spectacle correction did not show any statistically signiﬁcant changes. Binocular near visual acuity with best far spectacle
correction only showed signiﬁcant changes at 4 h post-instillation and at 1 month post-instillation
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Fig. 2 Trends in binocular far uncorrected visual acuity (a), defocus equivalent (b), and binocular near uncorrected visual
acuity (c) over time from 30 min to 1 month after instillation of the eye drops into the 28 studied eyes. Asterisks indicate
values that are signiﬁcantly different from the baseline. Binocular far uncorrected visual acuity and defocus equivalent did
not show any statistically signiﬁcant changes. Binocular near uncorrected visual acuity gradually improved over the course of
5 h following eye drop instillation
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Fig. 3 Trends in monocular far (a) and near (b) uncorrected visual acuity and intraocular pressure (c) over time from
30 min to 1 month after instillation of the eye drops into the 28 studied eyes. Asterisks indicate values that are signiﬁcantly
different from the baseline. Intraocular pressure was only signiﬁcantly lower at 5 h after eye drop instillation. Far
uncorrected visual acuity did not show any statistically signiﬁcant changes. Near uncorrected visual acuity gradually
improved over the course of 5 h following eye drop instillation
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Fig. 4 Trends in photopic pupil diameter (a), spherical equivalent (b), and scotopic pupil diameter (c) over time from
30 min to 1 month after instillation of the eye drops into the 28 studied eyes. Asterisks indicate values that are signiﬁcantly
different from the baseline. Pupil diameter under photopic conditions increased signiﬁcantly for the ﬁrst hour. Under
scotopic conditions, pupil diameter did not change signiﬁcantly until 3 h after eye drop instillation, and it then signiﬁcantly
decreased between 4 and 5 h after instillation. Spherical equivalent improved for 3 h following eye drop instillation
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DISCUSSION
Several studies have been conducted to
determine how much each factor involved in
the accommodative process contributes to it
[10–14]. The few topical treatments for
presbyopia currently under study claim to
work on different aspects of the
accommodative process: they involve
monovision parasympathetic-mediated miosis
and ciliary muscle stimulation or lens softening
in order to restore its shape-changing ability
[4–7]. Each of these approaches presents some
disadvantages. Pure parasympathetic
treatments result in a rather small pupil
diameter and a myopic shift, compromising
far distance vision, and they also cause several
well-known adverse reactions due to the
muscarinic stimulation of ciliary muscle and
pupil sphincter [5]. Even a safe lens-softening
treatment could be less effective than expected
because changes in mechanical properties seem
to be less important in the advent and
progression of presbyopia than changes in lens
geometry [12]. A monovision treatment could
reduce visual performance in reduced light
conditions compared to a binocular approach
[14]. For this reason, the treatment used in our
pilot study is instilled in both eyes. The
Vejarano (patent pending) eye drops both
stimulate the contraction of the ciliary body
and maintain a physiological pupil diameter
variation. In this context, binocular treatment
avoids the worsening of visual performance in
reduced light and allows physiological image
merging with clear focus at near, intermediate,
and distance. Pilocarpine provides both miosis
and ciliary body contraction, stimulating
accommodation, and may improve tear
production by stimulating lacrimal gland
secretion [15]. Phenylephrine, nepafenac, and
pheniramine, each in different ways and
amounts, stop excess pupil constriction and
counteract ciliary muscle spasm, vascular
congestion, and hyperemia induced by
pilocarpine [6, 16–18]. Naphazoline intensifies
the relaxing effect of pilocarpine on dilator
pupillae while relieving its side effects,
increasing acetylcholine release and reducing
norepinephrine release [18]. The lubricating
effect of polyethyleneglycol makes the eye
drops more tolerable by stopping the burning
sensation typically caused by most of the
compounds present in the eye drops. The
synergistic effect observed by Vejarano
between these compounds permits improved
near vision and preserves distance vision in all
subjects. The synergism reduces symptoms of
headache and hyperemia, allowing lower doses
of miotics to be used. There was no evidence of
tachyphylaxis in this study. No ocular
complications were detected in any of the
treated eyes during the entire follow-up
period. The results showed that UNVA
improved by about 2–3 lines in each eye and
binocularly from a baseline mean of about J 3.5
to about J 1.5. No patient presented any UDVA
degradation in an eye or binocularly. Whereas
other drops for treating presbyopia improve
near vision by causing extreme miosis or a
myopic shift that can reduce far vision [5],
refractive measurements performed in this
study showed there was a maximum myopic
shift of just 0.5 D, which progressively reduced
and disappeared after 3 h. Pupil diameter was
also measured and found to be mildly affected
by the topical treatment, so the mechanism for
near vision improvement might be due to
factors other than miosis. However, we cannot
clarify this issue based on the evidence provided
by the present study, so a controlled study of a
larger number of patients in which the dynamic
changes in refraction are investigated
objectively is required. Moreover, the
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measurements showed that the treatment
seemed to mitigate significant pupil
enlargement under scotopic conditions as
well as significant contraction under photopic
conditions. Other assessments showed that
there were no clinical changes in tear film
quality or quantity or in endothelial cell count,
showing that the eye drops had no adverse
effects on the lacrimal film, corneal
epithelium, or endothelial cells. The study
also showed that there was a significant
decrease in intraocular pressure of almost
2 mmHg 5 h after eye drop instillation. There
is clinical evidence that the trabecular
meshwork stiffens with age, which leads to
increased prevalence and incidence of
glaucoma with age [19]. The daily movement
of the scleral spur induced by the eye drops
could reduce this stiffening of the trabecular
meshwork, thereby suppressing the increase in
glaucoma incidence with age.
CONCLUSION
This preparation improves near vision by 2–3
lines without affecting far vision. Binocular
pharmacologic treatment of presbyopia with
the Vejarano (patent pending) eye drops has the
potential to ameliorate the reading vision of
presbyopes and has the advantages of a
nonmonovision therapy. This topical agent is
noninvasive and, we believe, meets all of the
criteria for an ideal treatment of presbyopia;
despite the small number and the heterogeneity
of the patients involved in this pilot study, its
findings suggest that this treatment is very
promising [20, 21]. Our group is currently
conducting a randomized controlled
double-masked clinical trial to test the
capacity of the Vejarano eye drops to improve
presbyopia.
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